Pioglitazone vs glimepiride: Differential effects on vascular endothelial function in patients with type 2 diabetes
Pioglitazone vs glimepiride: Differential effects on vascular endothelial function in patients with type 2 diabetes
复制标题
DOI：
10.1016/j.atherosclerosis.2008.11.027
复制
发表时间：
2009-07-01
期刊：
影响因子：
5.3
通讯作者：
Michalis, Lampros K.
中科院分区：
文献类型：
--
作者：
Papathanassiou, Katerina;Naka, Katerina K.;Michalis, Lampros K.
目的：本研究的目的是比较格列美脲和吡格列酮对已经接受二甲双胍治疗的2型糖尿病患者内皮功能的影响。方法：28例已接受二甲双胍治疗且无已知心血管疾病的2型糖尿病患者随机分为两组；A组（n = 14）加格列吡脲（4mg od）， B组（n = 14）加吡格列酮（30mg od），疗程6个月。所有患者在基线和随访时均评估肱动脉血流介导扩张（FMD）。结果：两组在年龄（平均+/- sd分别为63.6 +/- 7.3岁和62.8 +/- 7.2岁）或基线时的任何测量变量均无差异。两组空腹血糖和糖化血红蛋白的改善相似。两组随访时腰围绝对变化量差异有统计学意义，A、B组分别为+1.86 +/- 3.11 cm和-1.86 +/- 1.88 cm；空腹胰岛素水平，+14.79 +/- 12.56 pmol/L vs -25.84 +/- 28.09 pmol/L；稳态模型评估（HOMA）， +0.66 +/- 1.01 vs -1.83 +/- 1.38；HDL胆固醇水平，-0.07 +/- 0.22 mmol/L vs +0.14 +/- 0.20 mmol/L； FMD水平，+0.14 +/- 1.09% vs +2.02 +/- 2.05% (p
Objective: The aim of this study was to compare the effect of glimepiride and pioglitazone on endothelial function in patients with type 2 diabetes already on metformin.Methods: Twenty-eight patients with type 2 diabetes already on metformin without known cardiovascular disease, were randomized in 2 groups; glimepiride (4 mg od) was added in group A (n = 14) and pioglitazone (30 mg od) in group B (n = 14) for 6 months. Flow-mediated dilation (FMD) in the brachial artery was assessed in all patients, at baseline and at follow-up.Results: The 2 groups did not differ in age (mean +/- S.D., 63.6 +/- 7.3 years vs 62.8 +/- 7.2 years respectively), or any measured variable at baseline. Fasting glucose and glycated haemoglobin improved similarly in both groups. There were significant differences between the 2 groups in the absolute changes observed at follow-up in waist circumference, +1.86 +/- 3.11 cm vs -1.86 +/- 1.88 cm in groups A and B respectively; fasting insulin levels, +14.79 +/- 12.56 pmol/L vs -25.84 +/- 28.09 pmol/L; homeostasis model assessment (HOMA), +0.66 +/- 1.01 vs -1.83 +/- 1.38; HDL cholesterol levels, -0.07 +/- 0.22 mmol/L vs +0.14 +/- 0.20 mmol/L and FMD, +0.14 +/- 1.09% vs +2.02 +/- 2.05% (p